Logo 1.png
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 22, 2021 16:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
LOGO.png
The Greater Cannabis Company Announces Relisting to OTCQB
March 09, 2021 08:00 ET | The Greater Cannabis Company, Inc.
BALTIMORE, March 09, 2021 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTCQB: GCAN) (“the Company”), a biopharmaceutical company focused on development and commercialization of innovative...
Logo.jpg
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
February 26, 2021 09:20 ET | Biofrontera AG
Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...
Logo 1.png
Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
February 24, 2021 08:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
Logo 1.png
Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
February 19, 2021 13:25 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
logo.jpg
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021 22:24 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that...
Logo 1.png
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg
February 02, 2021 07:30 ET | Aeterna Zentaris Inc
- Company secures next step to continue to build-out pipeline of assets - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing...
Logo 1.png
Aeterna Zentaris to Present at NobleCon17
January 15, 2021 08:05 ET | Aeterna Zentaris Inc
– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET – CHARLESTON, S.C., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...
Logo.jpg
Biofrontera announces preliminary revenue figures for the full year 2020
January 08, 2021 09:35 ET | Biofrontera AG
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
logo.jpg
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 08, 2021 09:00 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc., (“Vallon” or the “Company”), a biopharmaceutical company focused on the development of novel drugs for CNS disorders,...